Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The "direct-to-employer" access model allows employers to work directly with a vendor to provide GLP-1 medications to eligible employees, bypassing PBMs, allowing for more pricing transparency and control
Semaglutide GLP-1 has shown promising results in weight loss among non-diabetic individuals, indicating its effectiveness extends beyond its initial purpose for managing diabetes
Plauth et al
Even if administered separately, co-administration without formal pharmacokinetic and pharmacodynamic evaluation cannot be considered safe
95% CI, 1.21 to 2.67) [35]
US$ 20.48
US$ 29.84
US$ 23.85
US$ 24.55
